Valneva Steps Up Its Roadshow as Technical Signals Flash Caution

Valneva is working two fronts this month: one in the conference halls of Belfast and New York, the other on the trading screens where its stock has been bleeding value. The Franco-Austrian vaccine developer is pitching its travel?vaccine portfolio to physicians and its pipeline prospects to institutional investors, all while trying to reverse a slide that has knocked more than a third off its share price since January.

The immediate catalyst for the commercial pitch is the 10th Northern European Conference on Travel Medicine (NECTM10) in Belfast, where Valneva appears as a gold sponsor and exhibitor. On the final day of the event it is hosting a symposium titled “From Risk to Protection: Practice Perspectives on Mosquito?Borne Diseases” — a direct nod to its chikungunya shot Ixchiq. The presentation targets the travel?medicine specialists who will be the front?line prescribers of that vaccine.

Alongside the Belfast appearance, Valneva has confirmed its participation in the Jefferies Global Healthcare Conference in New York this month, according to a recent SEC Form 6?K filing. The management team will also meet investors in Paris. The roadshow comes at a moment when the stock needs a narrative boost: the shares closed at €2.43, down 10.74% in a single week and 36.58% year?to?date. At that level the equity is trading 6.73% below its 50?day moving average of €2.61 and a steep 35.19% below the 200?day average of €3.76.

Technical indicators paint a conflicted picture. The relative strength index (RSI) sits at 82.5, normally a sign of overbought conditions — but with annualised 30?day volatility of 61.29% and the price hovering near its 52?week low of €2.25, the reading reflects short?term bounces rather than sustained momentum. The 52?week high of €5.16 from August 2025 now looks distant, and the shares have lost more than half their value from that peak.

Should investors sell immediately? Or is it worth buying Valneva?

Operationally, Valneva has a solid base: first?quarter product revenues came in at €30.5 million, and the company held €105.3 million in cash at the end of March. An €84 million capital increase closed in April adds further runway. Management has also launched a cost?cutting programme to tighten operating expenses.

The biggest valuation lever remains the Lyme disease vaccine candidate LB6V (formerly VLA15). Partner Pfizer is preparing regulatory filings after positive Phase 3 data, and any progress on that front could shift the market’s perception rapidly. Valneva is also advancing the shigella candidate S4V2, which it calls the most clinically advanced vaccine candidate against that infection globally.

Meanwhile, Ixchiq itself has landed a strategic win: Brazil’s health regulator ANVISA has approved local production by the Instituto Butantan, a move designed to make the vaccine accessible in middle? and low?income countries. Newly published four?year follow?up data show that 95% of study participants still have neutralising antibody titres after a single dose — a point Valneva is likely to emphasise at the upcoming events.

Valneva at a turning point? This analysis reveals what investors need to know now.

The busy calendar culminates at the end of June with the annual general meeting in Lyon, where the board is expected to sharpen the pipeline timeline and explain how the travel?vaccine business, cost discipline, and the Pfizer partnership fit together. For now, the share price is waiting for a catalyst that can break the technical downturn.

Ad

Valneva Stock: New Analysis - 3 June

Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Valneva analysis...

en | FR0004056851 | VALNEVA | boerse | 69474765 |